Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Choose breath, not death: Improving lung cancer screening in the Christus Good Shepherd internal medicine resident clinic.

Ogechi Ogonnaya Agogbuo, Siddanth Singh, Hiep Nguyen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23231

e23231 Background: Lung Cancer is by far the leading cause of cancer death, making up almost 25% of all cancer deaths. Shockingly, each year more people d...

Comprehensive profiling of cell-free DNAs to identify molecular characteristics related to advanced-stage triple-negative breast cancer in young women.

Maria Hafez, Chun Wang, Mouadh Barbirou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13137

e13137 Background: Breast cancer in young women is more likely to present as the triple-negative (TNBC) subtype compared to older women. Understanding the...

Association of socioeconomic status with secondary primary malignancy risk and mortality.

Flora Ho, Johnathan Guerrero, Baraka Muvuka Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21559

e21559 Background: Patients with a melanoma history are at higher risk of developing a secondary primary malignancy (SPM), an independent and distinct can...

Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework.

Akanksha Dua, Atul Butte, Travis Zack Jun 01, 2025 pp. 4186-4186 10.1200/jco.2025.43.16_suppl.4186

4186 Background: Completion of chemotherapy is crucial for clinical benefit and has been linked to improved outcomes, but is often challenging given the t...

Outcomes with nivolumab maintenance after autologous hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.

Parisa Aijaz, Ahmad Basharat, Umar Akram et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19037

e19037 Background: Hodgkin Lymphoma (HL) patients undergoing autologous stem cell transplantation (auto-SCT) remain at high risk for relapse, necessitatin...

Outcomes of prostate cancer patients hospitalized with viral respiratory illnesses: A national population-based study.

Amro Awad, Abdulsabur Sanni Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17008

e17008 Background: Prostate cancer patients are exposed to hormonal anti-androgenic therapy as a part of their treatment regimen. Previous studies compare...

Results and recommendations for surveillance/follow-up of breast cancer undergoing adjuvant hormonotherapy.

Thuan Minh Quang Tran, Thao Thi Phuong Tran, Thao Ngoc Phuong Tran et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23179

e23179 Background: We conducted a 10-year retrospective review to design post-treatment monitoring plans for breast cancer patients receiving endocrine th...

Trodelvy use in advanced triple negative breast cancer in Australia (TRACIE): Study design and interim analysis.

Vanessa Wong, Grace Kim, Yoland Catherine Antill et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13130

e13130 Background: Sacituzumab govitecan (SG) is a novel option for advanced triple-negative breast cancer (TNBC), offering improvement in progression-fre...

A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial.

Chang Gon Kim, Min Hee Hong, Jaehyung Kim et al. Jun 01, 2025 pp. 8040-8040 10.1200/jco.2025.43.16_suppl.8040

8040 Background: Although ALK inhibitors are approved for patients with ALK -positive recurrent and/or metastatic NSCLC or resecte...

Association of Claudin18.2 expression, PD-L1, and prognostic implications in gastric and gastroesophageal junction cancers.

Dani Ran Castillo, Mengni Guo, Kyung-il John Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16094

e16094 Background: CLDN18.2-targeted therapies and immune checkpoint inhibitors (ICIs) are promising approaches for gastri...

Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.

Hao Dai, Yao An Lee, Ying Lu et al. Jun 01, 2025 pp. 10508-10508 10.1200/jco.2025.43.16_suppl.10508

10508 Background: The use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has substantially expended given their remarkable benefits in managing o...

Codon 167 missense mutations in von Hippel-Lindau syndrome: Genotype-phenotype correlations in a population-based study.

Jianhui Qiu, Chuandong Wang, Jingcheng Zhou et al. Jun 01, 2025 pp. 10608-10608 10.1200/jco.2025.43.16_suppl.10608

10608 Background: Von Hippel-Lindau (VHL) disease is caused by germline mutations of the VHL gene, resulting in multicentric and m...

Fall risk assessment by QTUG device in geriatric cancer patients on chemotherapy at a tertiary care hospital.

Tilak Tvsvgk, Simran Kaur Bhatia, Vivek Aggarwal Jun 01, 2025 pp. 1533-1533 10.1200/jco.2025.43.16_suppl.1533

1533 Background: Age-related changes, such as declines in muscle strength, balance, and coordination, are exacerbated by cancer and its treatments elevati...

Disparities in pediatric oncology outcomes in the occupied Palestinian territories: A retrospective study from Augusta Victoria Hospital.

Ru'a Rimawi, Kendall Carpenter, Wesam Bader et al. Jun 01, 2025 pp. 1509-1509 10.1200/jco.2025.43.16_suppl.1509

1509 Background: Childhood cancer survival rates exceed 80% in high-income countries, but over 80% of the global burden occurs in low- and middle-income c...

Exploring prognostic nutritional index (PNI) and racial disparities in DLBCL.

Saivaroon Gajagowni, Hannah Kostan, Samuel Black et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19047

e19047 Background: DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), with a projected incidence of 32,443 new cases per year by 2025. Recent...

Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib.

Eric Jeffrey Sherman, Loren Scott Michel, Anuja Kriplani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18149

e18149 Background: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive form of thyroid cancer. The FDA has approved the use of dabrafenib and...

Head and neck cancer mortality: Unequal progress and emerging disparities.

Kyle Edwards, Chinmay Jani, Palash Asawa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13815

e13815 Background: Head and neck cancers (HNC) are often associated with significant morbidity due to their impact on essential functions such as speech,...

Incidence, predictors, and outcomes of venous thromboembolism in patients hospitalized with thyroid cancer: A nationwide analysis (2016–2021).

Krishna Kishore Anne, Ani Gvajaia, Michael Imeh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18152

e18152 Background: Patients with thyroid cancer (TC), although at lower overall risk of venous thromboembolism (VTE) compared to other malignancies, are a...

Real-world treatment patterns in stage III ALK+ NSCLC patients in China: A multicenter retrospective study.

Linlin Wang, Xiao Hu, Baoxing Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20077

e20077 Background: Stage III non-small cell lung cancer (NSCLC) is highly heterogeneous and ALK+ patients (pts) lack of standard treatment model. Thus, th...

Detection of circulating tumor cells and PTEN loss in localized prostate cancer before and after radical prostatectomy: Prognostic implications and predictors of treatment response.

Juliana Ramos Chaves, Andre Salim Khayat, Paula Souza et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17125

e17125 Background: There is a lack of reliable biomarkers to predict the recurrence of prostate cancer following prostatectomy, which can better guide sur...

Comparative effectiveness of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review and frequentist network meta-analysis.

Md. Imran Hossain, Ibrahim Khalil, M. Rafiqul Islam et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18564

e18564 Background: Tyrosine kinase inhibitors (TKIs) are highly effective for chronic myeloid leukemia (CML) carrying the BCR-ABL fusion gene. The advent...

Association of allostatic load (AL) and residential segregation with breast biopsy outcomes after screening mammography.

Braelyn Wekwerth, Niam Abeysiriwardena, Nathaniel Mercaldo et al. Jun 01, 2025 pp. 1620-1620 10.1200/jco.2025.43.16_suppl.1620

1620 Background: Allostatic Load (AL) and residential segregation have been associated with the risk of breast cancer (BC). However, the independent effec...

Exploring hidden risk: The prevalence of humoral immunodeficiency in patients with lymphoproliferative disorders—A prospective study.

Hassan Saeed, Syed Usman Mohsin Ehsanullah, Mouna Reghis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19083

e19083 Background: Infection is a significant cause of morbidity & mortality in patients with chronic lymphocytic leukemia (CLL), lymphoma, & mult...

The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.

Yin Li, Yan Zheng, Keneng Chen et al. Jun 01, 2025 pp. 4074-4074 10.1200/jco.2025.43.16_suppl.4074

4074 Background: The efficacy of neoadjuvant chemotherapy (NAC) vs primary surgery alone for treatment of locally advanced esophageal squamous cell carcin...

Demographic and clinical factors associated with sleep disturbance in breast cancer survivors.

Paulina S. Marell, Robert A. Vierkant, Nicole Larson et al. Jun 01, 2025 pp. 12083-12083 10.1200/jco.2025.43.16_suppl.12083

12083 Background: Fatigue and sleep disturbance are prevalent during and after cancer treatment; sleep-related symptoms affect 30-50% of patients with can...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page